This is a past event. Registration is closed. View other The Society of Gynecologic Oncology of Canada events.
Introduction
Janice Kwon
  • Janice Kwon (Gynecologic Oncologist, Professor and Vice Head, Department of Obstetrics and Gynecology at The University of British Columbia)

    Janice Kwon

    Gynecologic Oncologist, Professor and Vice Head, Department of Obstetrics and Gynecology at The University of British Columbia

    Dr. Kwon is a Gynecologic Oncologist, Professor and Vice Head of the Department of Obstetrics and Gynecology at UBC. She serves as Chair of the Priority and Evaluations Committee at BC Cancer, the Research & Outcomes Evaluation Committee for the BC Cancer Surgery Network, and the National BRCA Collaborative. Her expertise is in hereditary cancer syndromes and conducting cost-effectiveness analyses of testing criteria and risk-reducing interventions. Her background includes a Masters degree in Public Health from Harvard and post-doctorate at the University of Texas M.D. Anderson Cancer Center in Houston. She currently holds a Health Professional Investigator Award from the Michael Smith Foundation for Health Research.

    More information about speaker
Genetic Risk for Breast Cancer, 2022
Mark Robson

At the end of this session, participants will be able to:
1. Recognize the evolution of breast cancer clinical genetics over the last 28 years.
2. Describe the role of genetic testing in the management of people with or at risk for hereditary breast cancer.

  • Mark Robson (Medical oncologist, Chief, Breast Medicine Service at Memorial Sloan Kettering Cancer Center)

    Mark Robson

    Medical oncologist, Chief, Breast Medicine Service at Memorial Sloan Kettering Cancer Center
Germline testing and tumour testing in ovarian cancer
Janice Kwon

At the end of this session, participants will be able to:
1. Review germline testing and tumour testing in ovarian cancer
2. Describe the benefits of reflex tumour testing
3. Estimate the challenges of tumour testing

  • Janice Kwon (Gynecologic Oncologist, Professor and Vice Head, Department of Obstetrics and Gynecology at The University of British Columbia)

    Janice Kwon

    Gynecologic Oncologist, Professor and Vice Head, Department of Obstetrics and Gynecology at The University of British Columbia
Break
Genetic testing: Patient Experience and Resources
Jeanna McCuaig, MSc, PhD, CGC, CCGC

Resources from the Canadian Association of Genetic Counsellors.

At the end of this session, participants will be able to:
1. Identify genetic testing resources available from the CAGC.
2. Describe how resources may help clinicians facilitate genetic testing.

  • Jeanna McCuaig, MSc, PhD, CGC, CCGC (Genetic counsellor at Bhalwani Familial Cancer Clinic, Princess Margaret Cancer Centre)

    Jeanna McCuaig, MSc, PhD, CGC, CCGC

    Genetic counsellor at Bhalwani Familial Cancer Clinic, Princess Margaret Cancer Centre
Mainstreaming – patient experience
Jada Hamilton
  • Jada Hamilton (Associate Attending Psychologist at Memorial Sloan Kettering Cancer Center)

    Jada Hamilton

    Associate Attending Psychologist at Memorial Sloan Kettering Cancer Center

    Dr. Jada Hamilton is an Associate Member at Memorial Sloan Kettering Cancer Center, as well as an Associate Attending Psychologist in the Behavioral Sciences Service, Department of Psychiatry and Behavioral Sciences and in the Clinical Genetics Service, Department of Medicine at Memorial Hospital in New York, New York. Prior to joining the faculty of Memorial Sloan Kettering, Dr. Hamilton received a BA in Genetics and Psychology from Ohio Wesleyan University (2004), an MA and PhD in Social and Health Psychology from Stony Brook University (2006, 2009), and an MPH from the Mailman School of Public Health at Columbia University (2010). Dr. Hamilton also completed a postdoctoral fellowship as part of the National Cancer Institute’s Cancer Prevention Fellowship Program. Dr. Hamilton’s program of research addresses the intersection of behavioral science, cancer prevention, and genomics, with the goal of translating advances in genetic and genomic medicine into improved cancer care that is of high quality, aligned with patient preferences, and ultimately improves public health. She is currently leading a five-year study to assess how cancer patients and their families respond to inherited risk information that is revealed as part of tumor sequencing, and a study to examine the effects of novel breast cancer genetic risk feedback on patients’ decision-making, psychological, and behavioral outcomes. Outside of the lab, Dr. Hamilton enjoys baking and cooking, reading, competing with her pub trivia team, and exploring restaurants throughout New York City.

    More information about speaker
Introducing Ovarian Cancer Canada’s latest patient education resource: The power of genetics
Alison Ross

At the end of this session, participants will be able to:

1. Describe Ovarian Cancer Canada’s patient education tool for genetic testing.
2. Identify the gap that this tool is intended to fill.
3. Assess how the tool was developed and how it can be used.

  • Alison Ross (Director, Knowledge Mobilization of Ovarian Cancer Canada)

    Alison Ross

    Director, Knowledge Mobilization of Ovarian Cancer Canada
Break
Population-based testing
Ranjit Manchanda

At the end of this session, participants will be able to:
1. Identify the evidence base and rationale of population-based testing.
2. Describe the Pros and cons of population-based testing.
3. Assess the potential applicability of population-based testing.

  • Ranjit Manchanda (Professor of Gynaecological Oncology & Consultant Gynaecological Oncologist at Wolfson Institute of Population Health, Queen Mary University of London and Barts Health NHS Trust, London, UK)

    Ranjit Manchanda

    Professor of Gynaecological Oncology & Consultant Gynaecological Oncologist at Wolfson Institute of Population Health, Queen Mary University of London and Barts Health NHS Trust, London, UK
The Screen Project: Guided Direct-to-Consumer Genetic Testing for Cancer Susceptibility in Canada
Angelina Tryon, MS, CGC

At the end of this session, participants will be able to:
1. Identify the current BRCA genetic testing model in Canada and able to recognize gaps that exist.
2. Describe the study design and results (to date) for Phase II of The Screen Project.
3. Examine and distinguish case examples of newly-identified mutation carriers that pursued genetic testing through The Screen Project.

  • Angelina Tryon, MS, CGC (Genetic counsellor at Peter Gilgan Center for Women’s Cancers at the Women’s College Hospital & Research Institute)

    Angelina Tryon, MS, CGC

    Genetic counsellor at Peter Gilgan Center for Women’s Cancers at the Women’s College Hospital & Research Institute
Break
Ovarian cancer prevention strategies
Miranda Steenbeek MD, PhD

At the end of this session, participants will be able to:
1. Identify the risk of peritoneal carcinomatosis after risk-reducing salpingo-oophorectomy.
2. Describe the different strategies to reduce ovarian cancer risk.

  • Miranda Steenbeek MD, PhD (Radboud University Medical Centre)

    Miranda Steenbeek MD, PhD

    Radboud University Medical Centre
Introduction
Shannon Salvador•Danielle Vicus

At the end of this session, participants will be able to:
1. Understand the purpose of the meeting
2. Review the history of the CoPs

  • Shannon Salvador (Assistant Professor, Division of Gynecology Oncology, Segal Cancer Centre at McGill University - Jewish General Hospital)

    Shannon Salvador

    Assistant Professor, Division of Gynecology Oncology, Segal Cancer Centre at McGill University - Jewish General Hospital
  • Danielle Vicus (Gynecologic Oncologist at Sunnybrook Health Sciences Centre - Odette Cancer Centre)

    Danielle Vicus

    Gynecologic Oncologist at Sunnybrook Health Sciences Centre - Odette Cancer Centre
Meet the active CoPs
Danielle Vicus

At the end of this session, participants will be able to:
1. Name the current leaders and members of the Communities of practice and summarize the visions of the various CoPs.

  • Danielle Vicus (Gynecologic Oncologist at Sunnybrook Health Sciences Centre - Odette Cancer Centre)

    Danielle Vicus

    Gynecologic Oncologist at Sunnybrook Health Sciences Centre - Odette Cancer Centre
Icebreaker game
Cervantes Trial Discussion
Marie Plante

At the end of this session, participants will be able to:
1. Discuss the CERVANTES randomized trial of radical surgery followed by adjuvant (chemo) radiation versus no further treatment in patients with early-stage, intermediate-risk cervical cancer.

  • Marie Plante (Gynecologic Oncologist at Centre Hospitalier Universitaire de Quebec - L'Hotel dieu de Quebec)

    Marie Plante

    Gynecologic Oncologist at Centre Hospitalier Universitaire de Quebec - L'Hotel dieu de Quebec
Plenary
Danielle Vicus

At the end of this session, participants will be able to:
1. Identify the elements of the breakout.

  • Danielle Vicus (Gynecologic Oncologist at Sunnybrook Health Sciences Centre - Odette Cancer Centre)

    Danielle Vicus

    Gynecologic Oncologist at Sunnybrook Health Sciences Centre - Odette Cancer Centre
30-minute Breakouts

At the end of this session, participants will be able to:
1. Discuss what the CoPs have accomplished in 2022.
2. Explore the 2023 goals of the CoPs considering the following categories: education, research, and communications.
3. Select those who will represent the CoPs during the second breakout.

The list of Active CoPs:
• CoP in Cervix Cancer Prevention and Control
• CoP in ERAS & VTE
• CoP in GTN-GTD
• CoP in Immunotherapy
• CoP in LGSC and Rare Diseases
• CoP in Medical Cannabis
• CoP in MIS
• CoP in Obesity
• CoP in QI

Breakout Summaries

At the end of this session, participants will be able to:
1. Produce a summary of the discussion from the first breakout.

The list of Active CoPs:
• CoP in Cervix Cancer Prevention and Control
• CoP in ERAS & VTE
• CoP in GTN-GTD
• CoP in Immunotherapy
• CoP in LGSC and Rare Diseases
• CoP in Medical Cannabis
• CoP in MIS
• CoP in Obesity
• CoP in QI

Networking Break
Plenary
Danielle Vicus

At the end of this session, participants will be able to:
1. Identify the elements of the breakout.

  • Danielle Vicus (Gynecologic Oncologist at Sunnybrook Health Sciences Centre - Odette Cancer Centre)

    Danielle Vicus

    Gynecologic Oncologist at Sunnybrook Health Sciences Centre - Odette Cancer Centre
45-minute Breakouts

At the end of this session, participants will be able to:
1. Discuss the following themes: research, education, communications considering the impact of the 2023 projects, purpose and audience.

The list of departments:
• Research Unit
• Education
• Communications

2nd Breakout Summaries
Danielle Vicus

At the end of this session, participants will be able to:
1. Produce a summary of the discussion from the second breakout.

The list of departments:
• Research Unit
• Education
• Communications

  • Danielle Vicus (Gynecologic Oncologist at Sunnybrook Health Sciences Centre - Odette Cancer Centre)

    Danielle Vicus

    Gynecologic Oncologist at Sunnybrook Health Sciences Centre - Odette Cancer Centre
Conclusion
Danielle Vicus
  • Danielle Vicus (Gynecologic Oncologist at Sunnybrook Health Sciences Centre - Odette Cancer Centre)

    Danielle Vicus

    Gynecologic Oncologist at Sunnybrook Health Sciences Centre - Odette Cancer Centre

    Dr. Danielle Vicus is a gynecologic oncologist at the Odette Cancer Center, Sunnybrook Health Sciences Center. She completed her fellowship in Gynecologic Oncology at the University of Toronto and obtained a Master’s of Science in Clinical Epidemiology through the Institute of Health Policy, Management and Evaluation at the University of Toronto. She is currently an Associate Professor at the University of Toronto and an Affiliate Scientist at the Sunnybrook Research Institute.

    Dr. Vicus She is the GOC chair for the communities of practice and is a member of the GOC executive. She is also the QI (Quality Improvement) lead for the division of Gynecologic Oncology at Sunnybrook Health Sciences and is a voting member on the NRG Oncology Rare Tumour Cmt. Her key research interests are rare gynecologic tumours and cancer screening strategies in women. She has received multiple grants and awards during her career.

    More information about speaker
GOC Member’s Meeting – GOC’s Financials and Audit

Active Members only meeting